For this purpose, the use of OSCC mouse models, such as chemically induced mouse models, genetically modified mouse models, and transplanted (xenograft) models, is crucial.
Physiological and pathological changes were examined using islets from various mouse models such as non-obese diabetic (NOD), ob/ob, db/db mice and during pregnancy.
Substantial progress has been made in cell therapy strategies and in gene- and cytokine-introduced angiogenesis using a variety of mouse models, such as hind limb ischemia models.
Finally, we discuss emerging mouse models, such as second-generation pathophysiology models based on innovative approaches that are facilitated by the information gathered from the current genetic mouse models.
Gender-related phenotypic differences have been found in other long-lived mouse models such as the Ames dwarf mouse which shows a greater lifespan increase in females [13].
Recently also, autoantibodies have been implicated in several LSDs and their respective mouse models such as MPSIIIB [11], Batten disease [12] [15], and Gaucher disease [16], [17].
For more complex and SNP dense mouse models, such as heterogenous stock [7], [46], SNPs may have a more serious impact on DE of some genes.
Nr4a1-eGFP expression can be used to monitor the convergence of afferent pathways in vitro and in genetic mouse models such as cortex-specific deletion of BDNF or deletion of TH.
Recent studies have shown that IL-10 producing B-cell subsets with varying phenotypes can regulate different immune responses in numerous mouse models, such as inflammatory bowel disease (IBD), EAE, type 1 diabetes, collagen-induced arthritis, contact hypersensitivity and during parasitic infection [5].
